Quidel builds point-of-care respiratory infection panel with BARDA cash

By LabPulse.com staff writers

June 12, 2020 -- Quidel is developing a point-of-care diagnostic for respiratory infections using $635K in funding from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services.

The funding will support the development of a point-of-care diagnostic assay that tests for SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus. The respiratory virus panel would run on Quidel's Sofia 2 flagship instrument.

Sofia 2 is Quidel's next-generation version of its Sofia instrumented system. It uses the original Sofia fluorescent chemistry design while improving upon the graphical user interface and optics system to provide an accurate, objective, and automated result in 15 minutes, the firm said.

The BARDA funding began on May 29 and will run through April 2021. The goal of the funding is to achieve an emergency use authorization for the test by the U.S. Food and Drug Administration within the funding period, Quidel said.

Quidel gets amended clearance for coronavirus antigen tests
Quidel has received an amended emergency use authorization from the U.S. Food and Drug Administration to run its rapid antigen diagnostic test for the...
Quidel nets EUA, CE Mark for Lyra Direct SARS-CoV-2 assay
Quidel has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) and the CE Mark for its Lyra Direct SARS-CoV-2...
Quidel clearance signals arrival of rapid antigen tests for coronavirus
Clearance of Quidel's rapid antigen diagnostic test by the U.S. Food and Drug Administration marks the arrival of a third type of assay for the novel...
States ready to conduct more than 12.9M coronavirus tests in May
U.S. states will have the tests and lab supplies they need to conduct a total of more than 12.9 million coronavirus tests in May, covering more than...
Quidel receives expanded approval for COVID-19 test
The U.S. Food and Drug Administration has expanded Quidel's emergency use authorization for the company's Lyra SARS-CoV-2 assay, a real-time reverse transcription...

Copyright © 2020 LabPulse.com

Last Updated ls 6/12/2020 1:56:17 PM

Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.
Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current